DSGN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 27.80%

Insider Buying (Last 12 Months): $176,820.38

Insider Selling (Last 12 Months): $0.00

Design Therapeutics Insider Trading History Chart

Design Therapeutics Share Price & Price History

^$3.76

▲ +0.11 (3.01%)

As of 04/25/2024 01:00 AM ET

Days: 30 | 90 | 365

The “Next Bitcoin”? 10 CENT Crypto Set to Explode

From True Market Insiders | Ad

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Click For My #1 FREE Crypto for 2024

Design Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/25/2024	John P Schmid	Director	Buy	17,809	$3.74	$66,605.66	26,965
3/22/2024	John P Schmid	Director	Buy	9,156	$3.62	$33,144.72	9,156
9/29/2023	Rodney W Lappe	Director	Buy	21,000	$2.35	$49,350.00	133,024
8/29/2023	Deepa Prasad	Director	Buy	12,000	$2.31	$27,720.00	23,806
12/20/2022	Sr One Capital Fund I Aggregat	Major Shareholder	Buy	40,000	$8.14	$325,600.00	6,526,476
12/19/2022	Joao Md Siffert	CEO	Buy	1,150	$8.47	$9,740.50	126,319
12/19/2022	Simeon George	Director	Buy	360,000	$8.63	$3,106,800.00	6,486,476
12/16/2022	Simeon George	Director	Buy	500,000	$8.28	$4,140,000.00	6,126,476
12/9/2022	Rodney W Lappe	Director	Buy	15,000	$7.96	$119,400.00	112,024
3/21/2022	Arsani William	Director	Buy	25,000	$18.99	$474,750.00
3/18/2022	Stella Xu	Director	Sell	565,425	$19.07	$10,782,654.75
8/31/2021	Arsani William	Director	Buy	40,000	$15.45	$618,000.00

The “Next Bitcoin”? 10 CENT Crypto Set to Explode

From True Market Insiders | Ad

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Click For My #1 FREE Crypto for 2024

SEC Filings (Institutional Ownership Changes) for Design Therapeutics (NASDAQ:DSGN)

56.64% of Design Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Design Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/24/2024	Simplicity Wealth LLC	11,495	$46K	0.0%	N/A	0.020%
4/24/2024	Assenagon Asset Management S.A.	347,794	$1.40M	0.0%	+41.8%	0.616%
4/23/2024	BML Capital Management LLC	879,478	$3.54M	2.3%	-14.6%	1.557%
2/16/2024	Public Employees Retirement System of Ohio	26,338	$70K	0.0%	N/A	0.047%
2/14/2024	Pale Fire Capital SE	10,500	$28K	0.0%	N/A	0.019%
2/13/2024	Tower Research Capital LLC TRC	21,503	$57K	0.0%	+30.2%	0.038%
1/31/2024	Federated Hermes Inc.	11,999	$32K	0.0%	+317.6%	0.021%
1/30/2024	BML Capital Management LLC	1,029,478	$2.73M	2.1%	N/A	1.838%
1/25/2024	Nisa Investment Advisors LLC	11,560	$31K	0.0%	+38,433.3%	0.021%
11/15/2023	RTW Investments LP	2,512,986	$5.93M	0.1%	+60.8%	4.488%
11/14/2023	Corton Capital Inc.	27,134	$64K	0.0%	+56.6%	0.048%
11/14/2023	Prescott Group Capital Management L.L.C.	180,000	$0.43M	0.1%	N/A	0.321%
11/13/2023	Algert Global LLC	35,620	$84K	0.0%	+83.3%	0.064%
11/7/2023	Barclays PLC	71,678	$0.17M	0.0%	+353.1%	0.128%
11/7/2023	Jump Financial LLC	46,700	$0.11M	0.0%	+284.7%	0.083%
11/6/2023	Assenagon Asset Management S.A.	248,047	$0.59M	0.0%	-17.8%	0.443%
11/2/2023	Principal Financial Group Inc.	716,818	$1.69M	0.0%	-1.6%	1.280%
10/26/2023	Strs Ohio	72,800	$0.17M	0.0%	N/A	0.130%
10/13/2023	SG Americas Securities LLC	19,907	$47K	0.0%	N/A	0.036%
8/14/2023	UniSuper Management Pty Ltd	102,919	$0.65M	0.0%	N/A	0.184%
8/11/2023	Trexquant Investment LP	46,524	$0.29M	0.0%	-8.5%	0.083%
8/11/2023	ExodusPoint Capital Management LP	265,384	$1.67M	0.0%	+70.0%	0.474%
8/8/2023	Candriam S.C.A.	185,000	$1.17M	0.0%	N/A	0.331%
8/7/2023	Principal Financial Group Inc.	728,221	$4.59M	0.0%	+1.2%	1.302%
8/2/2023	Bank of Montreal Can	99,240	$0.63M	0.0%	N/A	0.177%
7/25/2023	Assenagon Asset Management S.A.	301,688	$1.90M	0.0%	+79.3%	0.539%
5/16/2023	Avoro Capital Advisors LLC	3,500,000	$20.20M	0.3%	+54.0%	6.256%
5/16/2023	Baker BROS. Advisors LP	626,884	$3.62M	0.0%	-9.4%	1.121%
5/11/2023	ExodusPoint Capital Management LP	156,138	$0.90M	0.0%	+207.8%	0.279%
5/9/2023	Principal Financial Group Inc.	719,937	$4.15M	0.0%	-8.0%	1.287%
5/8/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	19,306	$0.11M	0.0%	+15.7%	0.035%
5/3/2023	Jump Financial LLC	58,800	$0.34M	0.0%	+93.4%	0.105%
4/28/2023	SG Americas Securities LLC	15,040	$87K	0.0%	N/A	0.027%
4/18/2023	Assenagon Asset Management S.A.	168,215	$0.97M	0.0%	N/A	0.301%
2/15/2023	Avoro Capital Advisors LLC	2,272,222	$23.31M	0.3%	+2.3%	4.064%
2/14/2023	RA Capital Management L.P.	2,971,231	$30.49M	0.6%	+7.1%	5.314%
2/14/2023	EcoR1 Capital LLC	884,903	$9.08M	0.3%	-65.7%	1.583%
2/9/2023	Principal Financial Group Inc.	782,709	$8.03M	0.0%	-4.5%	1.400%
2/9/2023	Citigroup Inc.	109,660	$1.13M	0.0%	+220.0%	0.196%
2/8/2023	SR One Capital Management LP	6,526,476	$66.96M	24.4%	+16.0%	11.673%
2/7/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	16,689	$0.16M	0.0%	N/A	0.030%
11/15/2022	Bellevue Group AG	34,881	$0.58M	0.0%	N/A	0.062%
11/14/2022	Tudor Investment Corp Et Al	27,866	$0.47M	0.0%	+116.0%	0.050%
11/14/2022	Cormorant Asset Management LP	5,000,000	$83.60M	5.8%	-9.1%	8.943%
11/14/2022	RA Capital Management L.P.	2,773,231	$46.37M	1.0%	+26.8%	4.960%
11/14/2022	Integral Health Asset Management LLC	125,000	$2.09M	0.4%	N/A	0.224%
11/14/2022	MetLife Investment Management LLC	22,045	$0.37M	0.0%	+30.6%	0.039%
11/14/2022	Ghost Tree Capital LLC	100,000	$1.67M	0.5%	-63.6%	0.179%
11/10/2022	ExodusPoint Capital Management LP	51,841	$0.87M	0.0%	N/A	0.093%
11/8/2022	New York State Common Retirement Fund	24,246	$0.41M	0.0%	+11.1%	0.043%
11/7/2022	TD Asset Management Inc.	16,318	$0.27M	0.0%	-30.9%	0.029%
11/3/2022	Barclays PLC	21,598	$0.36M	0.0%	-89.5%	0.039%
11/1/2022	Tekla Capital Management LLC	280,523	$4.69M	0.2%	+158.8%	0.503%
10/31/2022	SG Americas Securities LLC	9,936	$0.17M	0.0%	-15.9%	0.018%
8/12/2022	Virtus ETF Advisers LLC	7,716	$0.11M	0.0%	N/A	0.014%
8/10/2022	Principal Financial Group Inc.	753,693	$10.55M	0.0%	+38.6%	1.351%
8/5/2022	State Board of Administration of Florida Retirement System	12,630	$0.18M	0.0%	N/A	0.023%
8/4/2022	TD Asset Management Inc.	23,618	$0.33M	0.0%	-46.7%	0.042%
7/29/2022	Tekla Capital Management LLC	108,414	$1.52M	0.1%	+65.9%	0.194%
7/29/2022	SG Americas Securities LLC	11,812	$0.17M	0.0%	N/A	0.021%
7/29/2022	Russell Investments Group Ltd.	2,344	$32K	0.0%	N/A	0.004%
6/30/2022	Amalgamated Bank	3,871	$63K	0.0%	N/A	0.007%
5/17/2022	Rock Springs Capital Management LP	345,597	$5.58M	0.1%	+3.1%	0.620%
5/16/2022	Ghost Tree Capital LLC	200,000	$3.23M	0.7%	+48.1%	0.359%
5/10/2022	TD Asset Management Inc.	44,318	$0.72M	0.0%	-32.6%	0.080%
5/9/2022	Principal Financial Group Inc.	543,912	$8.78M	0.0%	+4.1%	0.977%
5/9/2022	Qube Research & Technologies Ltd	20,396	$0.33M	0.0%	-11.5%	0.037%
5/5/2022	New York State Common Retirement Fund	21,876	$0.35M	0.0%	+68.8%	0.039%
4/28/2022	DekaBank Deutsche Girozentrale	18,700	$0.30M	0.0%	+10.0%	0.034%
2/16/2022	Ghost Tree Capital LLC	135,000	$2.89M	1.0%	N/A	0.243%
2/15/2022	SR One Capital Management LP	5,626,476	$120.46M	68.1%	N/A	10.108%
2/14/2022	Citadel Advisors LLC	2,534,702	$54.27M	0.0%	-1.5%	4.554%
2/10/2022	Qube Research & Technologies Ltd	23,052	$0.49M	0.0%	N/A	0.041%
2/9/2022	Principal Financial Group Inc.	522,454	$11.19M	0.0%	+136.9%	0.939%
2/8/2022	ProShare Advisors LLC	13,596	$0.29M	0.0%	N/A	0.024%
2/8/2022	Northern Trust Corp	212,015	$4.54M	0.0%	+72.6%	0.381%
2/7/2022	SG Americas Securities LLC	5,639	$0.12M	0.0%	N/A	0.010%
2/2/2022	New York State Common Retirement Fund	12,957	$0.28M	0.0%	+10.4%	0.023%
2/2/2022	DekaBank Deutsche Girozentrale	17,000	$0.34M	0.0%	N/A	0.031%
2/1/2022	Qube Research & Technologies Ltd	23,052	$0.49M	0.0%	N/A	0.041%
11/22/2021	EcoR1 Capital LLC	1,863,098	$27.37M	1.0%	+47.9%	3.347%
11/16/2021	Wellington Management Group LLP	955,588	$14.04M	0.0%	+1.7%	1.717%
11/16/2021	Citadel Advisors LLC	2,572,530	$37.79M	0.0%	+0.2%	4.622%
11/15/2021	Rock Springs Capital Management LP	334,050	$4.91M	0.1%	+0.6%	0.600%
11/15/2021	Piper Sandler & CO.	2,500	$37K	0.1%	N/A	0.004%
11/12/2021	Credit Suisse AG	235,938	$3.47M	0.0%	-1.8%	0.424%
11/12/2021	Geode Capital Management LLC	258,032	$3.79M	0.0%	+2.1%	0.464%
11/10/2021	Goldman Sachs Group Inc.	55,134	$0.81M	0.0%	+161.6%	0.099%
11/10/2021	Citigroup Inc.	24,808	$0.36M	0.0%	+4.7%	0.045%
11/9/2021	BlackRock Inc.	1,312,664	$19.28M	0.0%	-6.5%	2.360%
11/9/2021	Principal Financial Group Inc.	220,510	$3.24M	0.0%	+4.3%	0.396%
11/9/2021	TD Asset Management Inc.	65,718	$0.97M	0.0%	+208.2%	0.118%
10/22/2021	Strs Ohio	2,000	$29K	0.0%	-35.5%	0.004%
8/17/2021	Price T Rowe Associates Inc. MD	1,448,968	$28.17M	0.0%	+1.0%	2.605%
8/17/2021	Citadel Advisors LLC	2,566,148	$49.94M	0.0%	+1.2%	4.614%
8/16/2021	California State Teachers Retirement System	18,599	$0.37M	0.0%	N/A	0.033%
8/16/2021	Credit Suisse AG	240,158	$4.78M	0.0%	+291.0%	0.432%
8/16/2021	Pinz Capital Management LP	4,338	$86K	0.0%	N/A	0.008%
8/16/2021	Charles Schwab Investment Management Inc.	87,765	$1.75M	0.0%	N/A	0.158%
8/16/2021	State Street Corp	188,089	$3.74M	0.0%	N/A	0.338%

Data available starting January 2016

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Today's Range

Now: $3.76

$3.51

$3.79

50 Day Range

MA: $3.28

$2.48

$4.03

52 Week Range

Now: $3.76

$1.94

$8.47

Volume

217,668 shs

Average Volume

261,995 shs

Market Capitalization

$212.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.82

Who are the company insiders with the largest holdings of Design Therapeutics?: Design Therapeutics' top insider shareholders include:
Sr One Capital Fund I Aggregat (Major Shareholder)
Simeon George (Director)
Rodney W Lappe (Director)
Joao Md Siffert (CEO)
John P Schmid (Director)
Deepa Prasad (Director)
Learn More about top insider investors at Design Therapeutics.
Who are the major institutional investors of Design Therapeutics?: Design Therapeutics' top institutional shareholders include:
BML Capital Management LLC — 1.56%
Assenagon Asset Management S.A. — 0.62%
Simplicity Wealth LLC — 0.02%
Learn More about top institutional investors of Design Therapeutics stock.
Which major investors are selling Design Therapeutics stock?: Within the last quarter, DSGN stock was sold by these institutional investors:
BML Capital Management LLC
Which major investors are buying Design Therapeutics stock?: In the last quarter, DSGN stock was acquired by institutional investors including:
Assenagon Asset Management S.A.
Simplicity Wealth LLC
In the previous year, these company insiders have bought Design Therapeutics stock:
Sr One Capital Fund I Aggregat (Major Shareholder)
Simeon George (Director)
Rodney W Lappe (Director)
Joao Md Siffert (CEO)
John P Schmid (Director)
Deepa Prasad (Director)
Learn More investors buying Design Therapeutics stock.